Category: Research/Reports

ASAP 340B and AHA Outreach Documents Are Polar Opposites on 340B DSH Hospitals

In Pharma Industry, Providers, Research/ReportsJune 2, 2023786 Views

A new ASAP 340B document describes how its position on the 340B patient definition would play out under six hypothetical scenarios.

ASAP 340B, the group that drug manufacturers and community health centers formed to advance a joint 340B reform agenda, recently released a two-page explainer on how their plan would change the 340B patient definition. Under it, fewer drugs

…

340B Providers Don’t Systematically Over-Prescribe Brand Drugs for Profit, JAMA Study Says

In Research/ReportsMay 31, 2023453 Views

Laura Gilcrest

Research published in JAMA "found no meaningful difference in overall generic prescribing rates" between 340B and non-340B providers.

340B-eligible providers prescribe generic drugs at the same overall rate as non-340B providers, a study published in JAMA Health Forum found. “We found no evidence that 340B-eligible prescribers were systematically overprescribing brand-name drugs to generate revenue,” the authors

…

340B Grantees Need More Scrutiny as Drug Margins Rise, Gilead-funded Study Says

In Pharma Industry, Research/ReportsMay 25, 2023465 Views

Laura Gilcrest

340B contract pharmacy arrangements rose 252% for grantee covered entities between 2017 to 2022 compared to 194% for hospitals, a new drug company-funded study found.

Health centers and other federal grantees’ 340B savings and how they use them need more scrutiny, as these covered entities account for a large chunk of total 340B drug sales and their margins are keeping pace with those

…

HRSA and Prime Vendor Yank FAQs About 340B Use in Hospital Child Sites, and GAO Issues a New 340B Study

In Breaking, Federal, Regulatory, Research/ReportsMay 12, 20231852 Views

Tom Mirga

Excerpts from 340B FAQs that HRSA (top) and the 340B prime vendor Apexus (bottom) have removed from their websites.

The U.S. Health Resources and Services Administration midday yesterday and the 340B prime vendor Apexus this morning, in connection with the end of the COVID-19 public health emergency late last night, withdrew mostly identical 340B program FAQs about

…

340B Sales Growth Rate Softened for Second Straight Year, Data Show

In Pharma Industry, Research/ReportsMay 4, 2023559 Views

Tom Mirga

Prescription drug sales at 340B prices softened for the second consecutive year compared with sales growth from 2019 to 2020, data in a new IQVIA white paper show.

Prescription drug sales at 340B prices grew 12.2% year-on-year from 2021 to 2022, drug industry consulting and research firm IQVIA says in a new white paper. That is down 3.7 percentage points compared with 340B sales growth

…

340B Stifles Biosimilar Uptake, Study in Health Affairs Says

In Research/ReportsMay 2, 2023207 Views

Tom Mirga

New research in Health Affairs says 340B hospitals are less likely than others to use biosimilar drugs due to financial incentives to use more expensive reference drugs instead.

Research published online yesterday in the journal Health Affairs suggests that 340B hospitals are less likely than others to use biosimilar drugs, “possibly as a result of financial incentives making reference drugs more profitable than biosimilar medications.”

Groups

…

340B Hospitals Say Pharma’s Contract Pharmacy Policies Are Costing Them “Billions of Dollars”

In Pharma Industry, Providers, Research/ReportsMarch 23, 2023531 Views

Tom Mirga

340B Hospital savings by drug company bar chart

340B Health says, "For just the first five of the 21 drug companies for which there is a full year of data post-restrictions, the 340B savings for hospitals decreased by an estimated $1.1 billion from 2020 to 2021."

Hospitals’ 340B savings for the first five of the 21 companies to impose conditions on 340B pricing when providers use contract pharmacies decreased by an estimated $1.1 billion from 2020 to 2021, hospital group 340B Health said in

…

MedPAC’s Call to Replace Medicare DSH Formula Could Spill Over into 340B

In Federal, Research/ReportsMarch 16, 2023547 Views

Tom Mirga

MedPAC report to the Congress title page

MedPAC this week recommended replacing the Medicare DSH patient adjustment percentage for Medicare hospital payment purposes. The 340B program uses the same calculation as one of its hospital eligibility criteria.

Congressional Medicare advisers yesterday formally recommended replacing the formula Medicare uses to distribute extra payments to safety net hospitals that disproportionately serve low-income and/or uninsured beneficiaries.

The 340B program uses the same calculation—the Medicare disproportionate share adjustment percentage—to

…

One-Third of Americans Lack a Source of Primary Care and Health Centers Can Close the Gap, Says Report

In Providers, Research/ReportsFebruary 28, 2023145 Views

Tom Mirga

Map of United States depicting percentages of medically disenfranchised populations

Almost one-third of Americans lack access to a usual source of primary care, the National Association of Community Health Centers says in a new report.

More than 100 million Americans—almost one-third of the population, and many of them children—lack access to a usual source of primary care due to a shortage of providers in their community, leading to delays in care, poorer health

…

Study Raises Questions About Using 340B Claim Modifiers to Implement Medicare Drug Price Negotiation and Inflation Rebate Provisions

In Federal, Regulatory, Research/ReportsFebruary 22, 2023745 Views

Tom Mirga

IQVIA questions whether 340B claims identifiers can be used successfully to implement the Inflation Reduction Act's Medicare drug price negotiation and drug inflation rebate provisions.

New research by drug industry contractor IQVIA questions whether claims identifiers can be used successfully to exclude 340B-purchased drugs from new Medicare drug inflation rebates or to protect manufacturers from paying both a new negotiated Medicare price and

…

Breaking News

Site Footer